SIRT3 and Alzheimer disease: Notably, while the therapies of AD targeting at SIRT3 and SIRT5 is still limited and clinical data is far to reach, the strong SIRT1 activating compound resveratrol has enter into clinical trials for AD but regretfully without exciting results[148].